Health Claims

Liver transplant patients with fatty liver disease who took saroglitazar saw a small increase in belly fat and fat under the skin. This finding is from the abstract summary - full study details were not available

Descriptive

Taking saroglitazar didn't make the muscles weaker or more fatty in liver transplant patients with fatty liver disease. This finding is from the abstract summary - full study details were not available

Descriptive

When liver transplant patients with fatty liver disease had lower levels of a liver enzyme called alkaline phosphatase after treatment, their liver fat also tended to decrease more. This finding is from the abstract summary - full study details were not available

Correlational

About half of all patients and over 60% of those with higher initial liver fat saw their liver fat drop by at least 30% after taking saroglitazar for 24 weeks. This finding is from the abstract summary - full study details were not available

Descriptive

For people who had a liver transplant and have fatty liver disease, taking saroglitazar for 24 weeks lowered the amount of fat in their liver from about 10% to 8% on average. This finding is from the abstract summary - full study details were not available

Descriptive

When oxygen was low, MOTS-c treated diabetic rat hearts used less ATP, which may help protect the heart during low-oxygen events like heart attacks.

Correlational

MOTS-c treatment made the diabetic rats' heart cells have more mitochondria, which are the energy factories of cells.

Correlational

Diabetic rats given MOTS-c had lower blood sugar levels after fasting, showing better control of glucose.

Correlational

Diabetic rats had weaker heart mitochondria energy production, but MOTS-c treatment helped improve it back to normal levels.

Correlational

When diabetic rats were given MOTS-c daily for three weeks, their heart walls became slightly thinner, which is a sign of less heart enlargement.

Correlational

Apelin turns on genes that help build more mitochondria in muscles, improving energy production.

Descriptive

Apelin lowers blood fat levels and helps mice process sugar better, improving overall metabolic health.

Descriptive

Apelin's benefits for fat burning and mitochondria in muscles only work when AMPK is active, as shown in genetically modified mice.

Mechanistic

Apelin activates a key energy-sensing enzyme in muscles, which helps reduce fat buildup and improve metabolism.

Descriptive

Apelin-treated mice burn more fat for energy during active periods compared to placebo-treated mice, shown by their breathing patterns.

Descriptive

Apelin reduces harmful fat byproducts in muscles, which helps muscles take up more glucose in response to insulin.

Descriptive

Apelin makes mouse muscles produce more mitochondria, the cell's energy factories, leading to better fat-burning capacity.

Descriptive

Apelin helps mouse muscles use oxygen more efficiently for energy production, especially when using fat as fuel.

Descriptive

Apelin-treated mice burn fat more completely in their muscles compared to placebo-treated mice, reducing harmful fat byproducts.

Descriptive

Giving apelin to obese, insulin-resistant mice for a month helps them lose body fat and lowers their blood sugar levels compared to mice given a placebo.

Descriptive

Obese mice treated with MOTS-c had lower levels of ANGPTL4 in their muscles, which may help prevent fat buildup.

Quantitative

MOTS-c treatment in obese mice reduced the activity of a liver enzyme called Por by half, which may affect fat metabolism.

Quantitative

MOTS-c injections in obese mice lowered sebacate, a dicarboxylic acid, by 42% compared to untreated mice.

Quantitative

Obese mice given MOTS-c had lower levels of suberate, a dicarboxylic acid, by 40% compared to untreated mice.

Quantitative